Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07363694 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,156
- Enrollment target
NCT07363694: Recruiting Phase 2 study, sponsored by Pfizer.
NCT07363694 is a Phase 2 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 1,156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (769% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07363694, a Phase 2 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,156 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 35 to 80 years old * Have had moderate-to-severe COPD for at least 12 months * Have a documented history of at least 2 moderate or severe exacerbations within the last 12 months * Have been continuously taking their regular maintenance treatment(s) for COPD over at least 6 months at a stable dose for 3 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 24 weeks for the Phase 2 part and 52 weeks for the Phase 3 part. We will compare the results of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants who will be involved in the Phase 2 part of the study for about 40 weeks. During this time, they will have 11 visits at the study clinic. Participants who will be involved in the Phase 3 part of the study for about 68 weeks. During this time, they will have 18 visits at the study clinic.
Primary Outcome
FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 is obtained from spirometry.
Interventions
- DRUG Placebo
- DRUG PF-07275315 dose 1
- DRUG PF-07275315-dose 2
- DRUG PF-07275315-dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,156 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2031-01-16 |
| Phase | Phase 2 |
What NCT07363694 shows while recruiting
NCT07363694 is an interventional study that assigns participants to a tested intervention. Its 1,156 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (769% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07363694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07363694 about?
NCT07363694 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease". The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected. This st...
What is the current status of trial NCT07363694?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,156 participants. The study started on 2026-02-11. Estimated completion is 2031-01-16.
What interventions are being tested in trial NCT07363694?
The interventions under investigation include: Placebo (DRUG), PF-07275315 dose 1 (DRUG), PF-07275315-dose 2 (DRUG), PF-07275315-dose 3 (DRUG).
Who is sponsoring clinical trial NCT07363694?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07363694's enrollment target sits among peer trials
1,156 19th of 2000 higher than 1,982 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- NCT04474301 · 1,152 participants
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI